This article will not provide step-by-step mixing instructions, reconstitution ratios, or a personal dosing protocol for CJC-1295 or ipamorelin. These are unapproved compounds. Neither has standardized preparation or dosing guidelines validated through the clinical trial process. What can be reliably discussed is how these compounds have been studied for routes of administration and what peer-reviewed literature says, and does not say, about non-injectable administration forms like nasal sprays or oral tablets.
How to take CJC-1295 and Ipamorelin
A specific, step-by-step protocol for „how to take” cannot be responsibly provided. No published clinical study has established a validated self-administration procedure for any of these compounds. Existing studies reflect controlled clinical settings, not a guide for home use. What the literature does confirm is the general studied route of administration. The primary human study on CJC-1295 administered the compound subcutaneously in clinical research settings [1]. Pharmacokinetic studies of ipamorelin have used intravenous infusion in some studies [2] and nasal administration in others [3]. This reflects varying research designs, not a single agreed-upon consumer method.
No study has tested CJC-1295 and ipamorelin when administered together as a combined regimen in humans. Therefore, there is also no published data describing how both compounds would be administered together, in what order, or according to what combined schedule. Any specific shared „how-to-take” instructions circulating elsewhere do not originate from peer-reviewed clinical literature.
How to mix CJC-1295 and Ipamorelin
Reconstitution instructions go beyond what clinical trials for CJC-1295 and Ipamorelin actually investigated or reported. This includes things like the amount of bacteriostatic water per milligram of peptide or how to combine two different peptides in one vial. Published studies used a pre-mixed investigational drug. They did not describe a self-mixed procedure for the study, let alone for consumer replication. Providing specific reconstitution ratios, storage volumes, or numbers like „how much bac water per X mg” would present numbers unsupported by peer-reviewed data as established fact. This would contradict the goal of this series: avoiding fabricated details.
Reviews of this class of compounds have also noted something significant. The quality and consistency of products in the unregulated peptide supply chain is a real, documented problem. This means that even the starting material used for any reconstitution—its actual purity, concentration, or identity—cannot be assumed to be in accordance with what the label states [4]. For these reasons, this article does not provide mixing or reconstitution instructions.
CJC-1295 nasal spray and oral forms
There is significant, specific research on non-injection administration methods for this class of peptides. However, the details differ significantly between CJC-1295 and ipamorelin. Neither of these compounds is available in a nasal spray, oral tablet, or capsule form that has been established as clinically equivalent to an injection. For ipamorelin specifically, a pharmacokinetic study directly measured intranasal administration. It showed that bioavailability via this route is approximately 20%. This means that only about one-fifth of the dose reached the systemic circulation compared to an injection. This is significantly lower than some related growth hormone-releasing peptides tested in the same study, which showed bioavailability closer to 50% [3]. Intranasal administration of ipamorelin is therefore pharmacologically feasible and has been studied. However, it is measurably less effective than injection. This finding also comes from a controlled pharmacokinetic study, not from commercial intranasal spray products—the latter have not been validated based on these studies.
For CJC-1295, the peer-reviewed literature reviewed for this article did not contain a study measuring nasal absorption or bioavailability specifically for this compound. Claims of „CJC-1295 nasal spray" being pharmacologically equivalent to injection are therefore not supported by direct evidence identified herein.
Regarding oral forms – tablets, capsules, or pills – there is a well-established principle in peptide pharmacology worth knowing. Peptides such as CJC-1295 and ipamorelin are broken down by digestive enzymes in the stomach and intestines before they can be absorbed intact. This is precisely why injectable or nasal routes have been researched, rather than oral formulations.
There are separate studies on a structurally related but chemically distinct compound. NN703 is a small-molecule compound derived from the basic structure of ipamorelin but specifically modified to survive oral administration. In animal studies, it demonstrated oral bioavailability in the range of 30% [5]. However, this applied to a different, specially designed molecule—not ipamorelin or CJC-1295 themselves. None of the published human studies identified in this review demonstrate that CJC-1295 or ipamorelin, in their standard peptide forms, are effectively absorbed when administered as oral tablets or capsules.
Limitations of current evidence
Research on the administration methods for this class of compounds is truly informative in some places. The data on nasal bioavailability of ipamorelin are a good example. However, they do not extend to validated mixing instructions, reconstitution protocols, co-administration schedules, or confirmed oral or nasal spray products specifically for CJC-1295.
Where related but chemically distinct compounds, such as NN703, have been designed for oral administration, these studies do not extend to CJC-1295 or standard ipamorelin. Readers should exercise caution before assuming otherwise.
Disclaimer
This content is for educational and informational purposes only. It should not be interpreted as medical advice, preparation instructions, or a self-administration guide. CJC-1295 and ipamorelin remain research compounds. Neither is FDA or European Medicines Agency approved for any medical use, whether used individually or in combination. There is no validated reconstitution, mixing, or co-administration protocol for these compounds in peer-reviewed literature. Quality and purity of products in the unregulated peptide supply chain also remain a documented concern.
References
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
- Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
- Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1
- Hansen, B. S., Raun, K., Nielsen, K. K., Johansen, P. B., Hansen, T. K., Peschke, B., Lau, J., Andersen, P. H., & Ankersen, M. (1999). Pharmacological characterization of a new oral GH secretagogue, NN703. European Journal of Endocrinology, 141(2), 180–189. https://doi.org/10.1530/eje.0.1410180